SCHEMBL31358749

SCHEMBL31358749

O=C1C(=Cc2ccc(-c3cc(C(F)(F)F)ccc3Cl)o2)C(=O)c2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
PTPN1 P18031 3/20 0.47
ALDH1A1 P00352 2/20 0.47
CTDSP1 Q9GZU7 2/20 0.47
HPGD P15428 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
PPM1G O15355 1/20 0.47
PTPN7 P35236 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPRO Q16827 1/20 0.47
PTPN22 Q9Y2R2 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NTSR1 P30989 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SAE1 Q9UBE0 1/20 0.47
UBA2 Q9UBT2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358701 0.84 MAPT (0.65) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL31358737 0.82 PTPN5 (0.59) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL31358792 0.82 JAK2 (0.60) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL31358760 0.81 RXRA (0.58) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL13056359 0.81 SIRT2 (0.61) MEN1KMT2APOLBL3MBTL1GSK3A
SCHEMBL4030956 0.79 PTPN1 (0.50) MAPTMEN1KMT2APOLBPTPN1
SCHEMBL31358883 0.78 GSK3A (0.59) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL31358776 0.76 SIRT2 (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL31358707 0.76 MAPT (0.65) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL31358694 0.76 SIRT2 (0.67) MAPTMEN1KMT2APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 MAPT 4688/4885MEN1 2467/4885KMT2A 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.